Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
PLANO, Texas, April 23, 2018 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 after market close.
Nuvectra will hold a conference call on Wednesday, May 2, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 2896392. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on May 2, 2018 through May 9, 2018. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 2896392. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts:
Nuvectra Corporation
Walter Berger, COO & CFO
(214) 474-3102
[email protected]
Investor Contacts:
The Ruth Group
Tram Bui / Brian Johnston
(646) 536-7035 / 7028
[email protected]
